Centiva Capital’s Cytosorbents Corp CTSO Stock Holding History

Centiva Capital’s Portfolio CTSO Stock Details CTSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,737	Closed	-$10K	–	1332
2025 Q3	$10K	Buy	+10,737	New	+$10.6K	﹤0.01%	1001

Other funds holding CTSO

Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Centiva Capital's CTSO Position: Q4 2025 in Review

Centiva Capital sold out of Cytosorbents Corp (CTSO) in Q4 2025, closing a stake of 10,737 shares — an estimated $10K sold.

Centiva Capital first reported a position in CTSO in Q3 2025 and held it in 1 quarter. The position peaked at $10K in Q3 2025. 51 funds tracked by Wall St. Rank hold CTSO as of Q4 2025.

Centiva Capital reported no remaining Cytosorbents Corp position as of Q4 2025 after selling out during the quarter.
Centiva Capital sold 10,737 Cytosorbents Corp shares in Q4 2025, an estimated $10K.
Centiva Capital first reported a position in Cytosorbents Corp in Q3 2025 and held it in 1 quarter.
Centiva Capital's Cytosorbents Corp position peaked at $10K in Q3 2025.
51 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q4 2025.

Based on Centiva Capital's 13F filing for Q4 2025, filed 13 Feb 2026.